A new generation of physicians is reinvigorating the field of cardiac arrest research. I am grateful that two of the experts in this area have written this issue of EM Reports. After reading this, I anticipate you will place these principles into practice.
With advances in medical science, patients with serious congenital diseases are living into adulthood. Where once cystic fibrosis patients died in infancy, patients now live into their 40s. Although many of the standard treatments for COPD apply to cystic fibrosis, there are specific differences in management, which this monograph highlights.
You are treating a patient that you feel would be a good candidate for 'Drug X.' Unfortunately, 'Drug X' is not indicated by the FDA for the treatment of that specific condition; and, you are unable to find prescribing information regarding the optimal dose or duration of therapy with 'Drug X' for that condition. You realize that your use of 'Drug X' in this circumstance would be considered "off-label." What legal risks, if any, might you face?
Emergency physicians are much more likely to be sued for not administering tissue plasminogen activator (tPA) to stroke patients, than for giving the drug, says a new study.
